Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with
high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP)
undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Collaborators:
E.J. Whitten Foundation Prostate Cancer Research Centre Endocyte Medical Research Future Fund (MRFF) Movember Foundation